➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Baxter
Dow
McKesson
Boehringer Ingelheim

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,258,035

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,258,035
Title:Multi-mode communication ingestible event markers and systems, and methods of using the same
Abstract: A device including an integrated circuit, a partial power source, including first and second materials associated with the integrated circuit is disclosed. The first and second materials are configured to provide a voltage potential difference when in contact with a conductive fluid to power up the device. A signal amplification element secured around the integrated circuit relative to the first and second materials is configured to facilitate extension of a current flow path between the first and second materials. A modulator is configured to control conductance between the first and second materials to generate a detectable signal that is partially defined by the current flow extending through the conductive fluid. A communication module is coupled to the partial power source and is configured to communicate with a receiver and an antenna electrically coupled to the communication module, which uses the antenna to communicate with the receiver.
Inventor(s): Robertson; Timothy (Belmont, CA), Zdeblick; Mark (Portola Valley, CA)
Assignee: Proteus Digital Health, Inc. (Redwood City, CA)
Application Number:14/699,809
Patent Claim Types:
see list of patent claims
Device;

Drugs Protected by US Patent 9,258,035

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka Pharm Co Ltd ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-001 Nov 13, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Otsuka Pharm Co Ltd ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-002 Nov 13, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Otsuka Pharm Co Ltd ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-003 Nov 13, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Otsuka Pharm Co Ltd ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-004 Nov 13, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Otsuka Pharm Co Ltd ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-005 Nov 13, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
McKinsey
Colorcon
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.